Biopsy Devices Industry

The global biopsy devices market size was valued at USD 2.25 billion in 2023 and is expected to expand at a CAGR of 7.2% from 2024 to 2030. The rising prevalence of cancer, increasing emphasis on minimally invasive surgeries, the presence of untapped opportunities in emerging economies, especially in the Asia Pacific, and improving healthcare infrastructure are among the key trends encouraging industry growth.

According to the Union for International Cancer Control (UICC), more than 35 million new cases of cancer are estimated in 2050, which shows an increase of about 77% from the estimated 20 million cases in 2022.  This rise in cancer cases is expected to drive the demand for biopsy devices and foster market growth.

In addition, the advantages offered by minimally invasive procedures have driven their demand globally. These procedures result in the quicker recovery of patients and are less traumatic. The rising demand for minimally invasive procedures has further fostered innovation in the market. For instance, in July 2022, doctors introduced a new technology at NewYork-Presbyterian/Columbia, which offers a less invasive, safer, and more timely option to perform lung biopsy.

Gather more insights about the market drivers, restrains and growth of the Global Biopsy Devices market

Biopsy Devices Market Segments:

Product Insights

Needle-based biopsy guns dominated the market and accounted for the largest market share of 43.1% in 2023. The increasing demand for needle-based biopsy guns to collect samples from soft tissues of internal organs is driving the growth of the overall market. In addition, the rising need for rapid and gentle procurement of cell samples for biopsy has led to the development of technologically advanced biopsy devices such as vacuum-assisted biopsy (VAB) devices. For instance, in August 2022, Mammotome introduced a Vacuum-Assisted Breast Biopsy System, which can help in lesion excision. Such developments are likely to foster market growth.

The biopsy needle segment is expected to grow significantly over the forecast period. Technological advancements and the increasing demand for these needles to access difficult anatomy while performing biopsies are major drivers of segmental growth. The increasing innovation and launch of advanced products are further expected to drive segment growth. For instance, in May 2024, Cook introduced the biopsy needle EchoTip AcuCore EUS to be used in precision gastrointestinal lesion biopsies.

Regional Insights 

North America biopsy devices market dominated the overall global market and accounted for 43.1% of revenue share in 2023, Owing to rising cancer cases and the increasing development of technologically advanced biopsy devices in the region. For instance, in September 2023, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Limaca Medical's Precision GI endoscopic ultrasound biopsy device. Such developments in the region are expected to foster further growth in the market.

Browse through Grand View Research's Medical Devices Industry Research Reports.

1. The global neurology ultrasonic market size was valued at USD 430.1 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 5.6% from 2024 to 2030.

2. The global collateral ligament stabilizer system market size was valued at USD 2.08 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2030.

Key Biopsy Devices Company Insights

Some players in the market include Cardinal Health Inc., Hologic, Inc., and Danaher Corporation, and others. These players are majorly engaged in R&D to develop technologically advanced products to help them retain a strong position in the market. For instance, in August 2022, Devicor Medical Products, Inc. introduced the Mammotome DualCore Dual Stage Core Biopsy System, which is expected to help the company in advancing its biopsy device portfolio.

1. Cardinal Health, Inc. is a global healthcare services and products company operating majorly in two segments: Pharmaceutical and Medical. The company also engages in the production of minimally invasive biopsy devices such as fine needle core biopsy (FNCB), bone marrow biopsy & aspiration needles, and Tissue Biopsy Kits.

2. Hologic, Inc. is a global company engaged in developing, manufacturing, and supplying medical imaging systems, diagnostic products, and surgical products, including biopsy devices. The company has introduced advanced biopsy devices such as the Eviva Breast Biopsy system, and Brevera breast biopsy system to gain a competitive edge.

Key Biopsy Devices Companies:

The following are the leading companies in the biopsy devices market. These companies collectively hold the largest market share and dictate industry trends.

1. Cardinal Health Inc.

2. Hologic, Inc.

3. Danaher Corporation

4. CONMED Corporation

5. Cook Medical

6. DTR Medical

7. INRAD, Inc.

8. Devicor Medical Products Inc.

9. Gallini Srl

10. TransMed7, LLC.

Segments Covered in the Report

Grand View Research has segmented the global biopsy devices market report on the basis of product and region:

Biopsy Device Product Outlook (Revenue, USD Million, 2018 - 2030)

1. Needle-based Biopsy Guns

   1. Vacuum-assisted Biopsy (VAB) Devices

   2. Fine Needle Aspiration Biopsy (FNAB) Devices

   3. Core Needle Biopsy (CNB) devices

2. Biopsy Guidance Systems

   1. Manual

   2. Robotic

3. Biopsy Needles

   1. Disposable

   2. Reusable

4. Biopsy Forceps

   1. General Biopsy Forceps

   2. Hot Biopsy Forceps

5. Others

   1. Brushes

   2. Curettes

   3. Punches

Biopsy Device Regional Outlook (Revenue, USD Million, 2018 - 2030)

1. North America

   1. US

   2. Canada

2. Europe

   1. UK

   2. Germany

   3. France

   4. Italy

   5. Spain

   6. Denmark

   7. Sweden

   8. Norway

3. Asia Pacific

   1. Japan

   2. India

   3. China

   4. South Korea

   5. Thailand

   6. Australia

4. Latin America

   1. Brazil

   2. Mexico

   3. Argentina

5. Middle East & Africa

   1. South Africa

   2. Saudi Arabia

   3. UAE

   4. Kuwait

Recent Developments

1. In April 2024, Single Pass announced the FDA clearance of the Kronos biopsy closure device, its class II medical device.

2. In May 2023, Argon Medical Devices introduced the SuperCore Advantage semi-automatic biopsy instrument, a soft tissue biopsy product in the U.S.

3. In February 2023, TransMed7 announced its plans to introduce its US-guided biopsy devices.

Order a free sample PDF of the Biopsy Devices Market Intelligence Study, published by Grand View Research.